CeriBell (NASDAQ:CBLL) Receives Average Rating of “Buy” from Brokerages

CeriBell (NASDAQ:CBLL) has earned an average recommendation of “Buy” from the six brokerages that are covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $32.60.

A number of research firms have recently commented on CBLL. TD Cowen raised their target price on CeriBell from $31.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Canaccord Genuity Group reiterated a “buy” rating and set a $33.00 price objective on shares of CeriBell in a research note on Wednesday, February 26th.

CeriBell Price Performance

CBLL opened at $22.69 on Monday. The company has a 50 day moving average price of $22.93. CeriBell has a 52 week low of $18.69 and a 52 week high of $32.75.

CeriBell (NASDAQ:CBLL) last released its earnings results on Tuesday, February 25th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). The firm had revenue of $18.53 million during the quarter, compared to the consensus estimate of $17.55 million. As a group, research analysts expect that CeriBell will post -2.46 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Woodline Partners LP bought a new stake in shares of CeriBell in the 4th quarter worth $2,588,000. Yu Fan bought a new stake in shares of CeriBell in the 4th quarter worth $31,631,000. TPG GP A LLC bought a new stake in shares of CeriBell in the 4th quarter worth $102,677,000. RTW Investments LP bought a new stake in shares of CeriBell in the 4th quarter worth $3,882,000. Finally, Red Tree Management LLC bought a new stake in shares of CeriBell in the 4th quarter worth $57,083,000.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.